MarketCap
Ascendis Pharma A/S ASND
$ 256.21
-1.28%
Facebook
X
Telegram
Ascendis Pharma A/S ROCE Ratio | ASND
Annual ROCE Ratio Ascendis Pharma A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -58.44 | -102.63 | -511.4 | -61.17 | -45.89 | -35.67 | -36.06 | -55.26 | -59.58 | -41.29 | -34.76 | -26.17 | - | - | - |
Annual performance
Select metrics to display
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -26.17 | -511.4 | -89.03 |
Quarterly ROCE Ratio Ascendis Pharma A/S
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -83.09 | -87.19 | -131.61 | 52.01 | -1279.78 | -1321.02 | -1303.48 | -1474.78 | -102.46 | -77.41 | -69.84 | -59.25 | -50.53 | -45.91 | -42.03 | -45.37 | -49.35 | -45.95 | -53.43 | -51.01 | -37.04 | -44.85 | -44.12 | -35.44 | -22.81 | -35.4 | -41.28 | -44.1 | -36.39 | -51.96 | -58.88 | -60.42 | -50.29 | -15.57 | -19.5 | -15.22 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 52.01 | -1474.78 | -192.63 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Geron Corporation
GERN
|
-14.94 | $ 0.96 | -3.71 % | $ 640 M |  USA |
 |
Bristol-Myers Squibb Company
BMY
|
5.3 | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-186.76 | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-45.76 | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
-54.02 | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-141.54 | $ 4.0 | -6.76 % | $ 48.8 M |  Israel |
 |
Allena Pharmaceuticals
ALNA
|
-53.64 | - | 3.16 % | $ 1.9 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
2.69 | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
21.04 | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
TCR2 Therapeutics
TCRR
|
-108.97 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-52.09 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
-228.86 | - | -60.05 % | $ 125 K | USA |
 |
Mesoblast Limited
MESO
|
-13.2 | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
37.04 | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-580.3 | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
6.25 | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-13.43 | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
-31.94 | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
19.69 | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
-29.7 | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Axcella Health
AXLA
|
-1848.9 | - | -16.42 % | $ 249 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-0.69 | - | - | $ 2.02 B | USA |
 |
Intellia Therapeutics
NTLA
|
-59.74 | $ 11.18 | -7.72 % | $ 1.21 B | USA |
 |
Novartis AG
NVS
|
21.09 | $ 163.39 | -0.18 % | $ 317 B |  Schweiz |
 |
Omeros Corporation
OMER
|
101.29 | $ 17.3 | -1.48 % | $ 1.1 B | USA |
 |
Oramed Pharmaceuticals
ORMP
|
-7.12 | $ 3.97 | -0.75 % | $ 164 M | Israel |
 |
Tyme Technologies
TYME
|
-31.86 | - | 8.07 % | $ 54 M | USA |
 |
Puma Biotechnology
PBYI
|
27.62 | $ 8.13 | -3.22 % | $ 407 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
-340.95 | $ 1.02 | -5.09 % | $ 47.3 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-47.25 | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Pfizer
PFE
|
10.69 | $ 29.34 | 0.36 % | $ 167 B | USA |
 |
Завод ДИОД
DIOD
|
5.84 | - | - | - |  Russia |
 |
PainReform Ltd.
PRFX
|
-58.14 | $ 0.78 | -4.24 % | $ 505 K | Israel |
 |
Prothena Corporation plc
PRTA
|
-75.06 | $ 8.56 | -2.51 % | $ 461 M | USA |
 |
Arcus Biosciences
RCUS
|
-61.17 | $ 18.66 | -1.56 % | $ 2 B | USA |
 |
Orgenesis
ORGS
|
155.73 | - | -33.86 % | $ 61.2 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
19.81 | $ 14.9 | -1.03 % | $ 12.4 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
11.45 | $ 916.16 | -0.41 % | $ 95.8 B | USA |
 |
Replimune Group
REPL
|
-116.69 | $ 23.3 | 4.67 % | $ 2.16 B | USA |
 |
Фармсинтез
LIFE
|
-4.03 | - | - | - | Russia |
 |
Royalty Pharma plc
RPRX
|
8.21 | $ 69.47 | 1.02 % | $ 29.9 B | USA |
 |
Revolution Medicines
RVMD
|
-57.28 | $ 193.0 | -3.57 % | $ 36.7 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-78.92 | $ 113.99 | 0.04 % | $ 7.41 B | USA |
 |
Codiak BioSciences
CDAK
|
-129.99 | - | -55.98 % | $ 2.15 M | USA |
 |
Sana Biotechnology
SANA
|
-74.02 | $ 2.43 | -1.42 % | $ 615 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-31.74 | $ 61.81 | 0.11 % | $ 172 M | Israel |
 |
Summit Therapeutics
SMMT
|
-57.38 | $ 17.78 | -0.34 % | $ 13.3 B | Britain |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-66.67 | $ 9.43 | -0.89 % | $ 817 M | USA |
 |
Spero Therapeutics
SPRO
|
10.7 | $ 1.01 | -5.61 % | $ 56.6 M | USA |